Regeneron Pharmaceuticals Revenue 2006-2021 | REGN
For a detailed definition, formula and example for Revenue, check out our new background page here.
Regeneron Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Regeneron Pharmaceuticals revenue for the quarter ending June 30, 2021 was $5.139B, a 163.24% increase year-over-year.
- Regeneron Pharmaceuticals revenue for the twelve months ending June 30, 2021 was $12.384B, a 67.64% increase year-over-year.
- Regeneron Pharmaceuticals annual revenue for 2020 was $8.497B, a 29.58% increase from 2019.
- Regeneron Pharmaceuticals annual revenue for 2019 was $6.558B, a 27.44% increase from 2018.
- Regeneron Pharmaceuticals annual revenue for 2018 was $5.146B, a 12.37% decline from 2017.
Regeneron Pharmaceuticals Annual Revenue
(Millions of US $) |
| 2020 |
$8,497 |
| 2019 |
$6,558 |
| 2018 |
$5,146 |
| 2017 |
$5,872 |
| 2016 |
$4,860 |
| 2015 |
$4,104 |
| 2014 |
$2,820 |
| 2013 |
$2,105 |
| 2012 |
$1,378 |
| 2011 |
$446 |
| 2010 |
$459 |
| 2009 |
$379 |
| 2008 |
$238 |
| 2007 |
$125 |
| 2006 |
$63 |
| 2005 |
$66 |
Regeneron Pharmaceuticals Quarterly Revenue
(Millions of US $) |
| 2021-06-30 |
$5,139 |
| 2021-03-31 |
$2,529 |
| 2020-12-31 |
$2,423 |
| 2020-09-30 |
$2,294 |
| 2020-06-30 |
$1,952 |
| 2020-03-31 |
$1,828 |
| 2019-12-31 |
$1,864 |
| 2019-09-30 |
$1,744 |
| 2019-06-30 |
$1,578 |
| 2019-03-31 |
$1,373 |
| 2018-12-31 |
$363 |
| 2018-09-30 |
$1,664 |
| 2018-06-30 |
$1,608 |
| 2018-03-31 |
$1,512 |
| 2017-12-31 |
$1,582 |
| 2017-09-30 |
$1,501 |
| 2017-06-30 |
$1,470 |
| 2017-03-31 |
$1,319 |
| 2016-12-31 |
$1,227 |
| 2016-09-30 |
$1,220 |
| 2016-06-30 |
$1,213 |
| 2016-03-31 |
$1,201 |
| 2015-12-31 |
$1,098 |
| 2015-09-30 |
$1,137 |
| 2015-06-30 |
$999 |
| 2015-03-31 |
$870 |
| 2014-12-31 |
$802 |
| 2014-09-30 |
$726 |
| 2014-06-30 |
$666 |
| 2014-03-31 |
$626 |
| 2013-12-31 |
$610 |
| 2013-09-30 |
$597 |
| 2013-06-30 |
$458 |
| 2013-03-31 |
$440 |
| 2012-12-31 |
$415 |
| 2012-09-30 |
$428 |
| 2012-06-30 |
$304 |
| 2012-03-31 |
$232 |
| 2011-12-31 |
$123 |
| 2011-09-30 |
$103 |
| 2011-06-30 |
$108 |
| 2011-03-31 |
$112 |
| 2010-12-31 |
$134 |
| 2010-09-30 |
$106 |
| 2010-06-30 |
$116 |
| 2010-03-31 |
$104 |
| 2009-12-31 |
$97 |
| 2009-09-30 |
$117 |
| 2009-06-30 |
$90 |
| 2009-03-31 |
$75 |
| 2008-12-31 |
$56 |
| 2008-09-30 |
$66 |
| 2008-06-30 |
$61 |
| 2008-03-31 |
$56 |
| 2007-12-31 |
$65 |
| 2007-09-30 |
$22 |
| 2007-06-30 |
$22 |
| 2007-03-31 |
$16 |
| 2006-12-31 |
$10 |
| 2006-09-30 |
$16 |
| 2006-06-30 |
$19 |
| 2006-03-31 |
$18 |
| 2005-12-31 |
$17 |
| 2005-09-30 |
$16 |
| 2005-06-30 |
$16 |
| 2005-03-31 |
$16 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$61.217B |
$8.497B |
|
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
|
